Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis by Qi Xu, Xiaoyu Feng, Siyuan Qin, Yu Hong, Rui Cui, Jia Liang, Zhuya Xiao, Yuan Li

Subjects: Get full text

Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models by Liu Y, Wang X, Zhang N, He S, Zhang J, Xu X, Song S

Subjects: Get full text

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis by Maria Inez Dacoregio, Isabella Michelon, Caio Ernesto do Rego Castro, Francisco Cezar Aquino de Moraes, Guilherme Rossato de Almeida, Lis Victória Ravani, Maysa Vilbert, Ricardo Lima Barros Costa

Subjects: Get full text

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development by Whi-An Kwon, Ho Kyung Seo, Geehyun Song, Min-Kyung Lee, Weon Seo Park

Subjects: “…antibody–drug conjugates…”
Get full text

Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects by Yufei Wang, Guangliang Li, Hanying Wang, Quan Qi, Xian Wang, Haiqi Lu

Subjects: Get full text

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus by Emad Dawoud, Fathi Azribi, Aref Chehal, Shaheenah Dawood, Syed Hammad Tirmazy, Dina Hamza, Hassan Jaafar, Hussam Marashi

Subjects: Get full text

Biparatopic antibodies: therapeutic applications and prospects by David L. Niquille, Kyle M. Fitzgerald, Nimish Gera

Subjects: Get full text

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan by Ünal Metin Tokat, Ashkan Adibi, Ashkan Adibi, Esranur Aydın, Şevval Nur Bilgiç, Eylül Özgü, Onur Tutar, Mutlu Demiray

Subjects: Get full text

EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells by Bita Jafary, Mostafa Akbarzadeh-Khiavi, Hamed Farzi-Khajeh, Azam Safary, Khosro Adibkia

Subjects: “…Antibody-drug conjugates (ADCs)…”
Get full text

Clinical advances in antibody-drug conjugates for hematological malignancies by TANG Sijie, MI Jianqing

Subjects: “…antibody-drug conjugate (adc)…”
Get full text

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre by Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, April A. N. Rose, Parvaneh Fallah

Subjects: Get full text

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer by Riqing Huang, Anqi Hu, Qixiang Rong, Ditian Shu, Meiting Chen, Wei Yang, Yue Zhang, Qiufan Zheng, Xin An, Cong Xue, Haifeng Li, Yanxia Shi

Subjects: Get full text

Electrostatic properties of human germlines and biodistribution of small biologics by Leticia Maria De Souza Cordeiro, Kelley Christine Atkinson, Argin Aivazian, Patrick Frank Joyce, Fang Jia, Alessandro Mascioni

Subjects: Get full text

Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates by Yangyang Gao, Yuwei Xia, Yixin Chen, Shiqi Zhou, Yingying Fang, Jieru Yu, Leyin Zhang, Leyin Zhang, Leitao Sun, Leitao Sun, Leitao Sun

Subjects: “…antibody-drug conjugate…”
Get full text

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer by Hanghang Ma, Jianbin Li

Subjects: “…Antibody-drug conjugate…”
Get full text

Treatment approaches in advanced penile cancer: targeted therapies and immunotherapy by David J. Benjamin, Robert C. Hsu

Subjects: Get full text

A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors by Chenfei Zhou, Bin Wang, Christina Teng, Hui Yang, Sarina A. Piha-Paul, Gary Richardson, Ashanya Malalasekera, Yajun Sun, Wei Wang, Jieqiong Liu, Yan Shi, Xianbao Zhan, Charlotte Lemech

Subjects: “…Antibody–drug conjugate…”
Get full text

Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer by Trudy J. Philips, Britt K. Erickson, Stefani N. Thomas

Subjects: Get full text

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity by Alyssa Synan, Nila C. Wu, Roberto Velazquez, Thomas Gesner, Claude Logel, Kathrin Mueller, Andrew Green, Patrizia Barzaghi-Rinaudo, Quincey Simmons, Samuele Mercan, Xingyi Shi, Xun Li, Vivek Sagar, Joshua Korn, Margaret McLaughlin, William R. Tschantz, Dominik Hainzl, Anthony Malamas, Thomas Huber, Regis Cebe, Kathleen T. Xie, Joseph A. D’Alessio

Subjects: “…Antibody–drug conjugate…”
Get full text

A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan by Takamichi Ito, Yuka Tanaka, Dai Ogata, Haruto Nishida, Tatsushi Shiomi, Ryo Tanaka, Aya Kawaguchi, Azusa Miyashita, Satoshi Fukushima, Naoko Shojiguchi, Hiroyuki Goto, Yaei Togawa, Takahiro Kiyohara, Yoshinao Oda, Takeshi Nakahara

Subjects: Get full text